Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53 mutation...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Dreger, Peter, Schetelig, Johannes, Andersen, Niels, Corradini, Paolo, van Gelder, Michel, Gribben, John, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Stilgenbauer, Stephan, Montserrat, Emili
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2014
Soggetti:
Perspectives
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4276025/
https://ncbi.nlm.nih.gov/pubmed/25301705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-586826
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi